Skip to main content
. 2021 Dec 1;2(1):41–49. doi: 10.1016/j.jncc.2021.11.006

Fig. 4.

Fig 4

Progression-free survival of anti-PD-L1 vs anti-PD-1 in TMB-High and TMB-Low subgroups. Squares indicate mirror-specific HRs of indirect comparison of anti-PD-L1 vs anti-PD-1. Horizontal lines indicate 95% CrIs. Diamonds represent the meta-analytic pooled HRs (95% CrIs) in the TMB-High and TMB-Low groups. MYSTIC1 refers to the comparison of durvalumab to platinum-based doublet chemotherapy and MYSTIC2 refers to the comparison of durvalumab plus tremelimumab to platinum-based doublet chemotherapy. CheckMate-2273 refers to the comparison of nivolumab to platinum-based doublet chemotherapy and CheckMate-2274 refers to the comparison of nivolumab plus Ipilimumab to platinum-based doublet chemotherapy. Abbreviations: Crls, credible interval; HR, hazard ratio; PD-1, programmed cell death-1; PD-L1, programmed cell death-ligand 1; PFS, progression-free survival; TMB, tumor mutation burden.